Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00109733 · ClinicalTrials.gov registry record · Phase 3
Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency
A Phase 3 study, sponsored by EMD Serono.
- Completed
- Registry status
- Phase 3
- Development phase
- 31
- Enrollment target
NCT00109733 is a Phase 3 study that has completed, run by EMD Serono. The registered enrollment target is 31 participants.
The verdict
NCT00109733, a Phase 3 study, has completed, sponsored by EMD Serono.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 31 participants
- Enrollment target
Study Summary
The primary objective is to evaluate the efficacy and safety of two different dose regimens of r-hGH (Saizen®) in subjects with childhood-onset growth hormone deficiency (COGHD) during the transition phase from childhood to adulthood.
Interventions
- BIOLOGICAL recombinant human growth hormone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2005-01 |
| Est. Completion | 2006-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00109733
The ClinicalTrials.gov registry entry for NCT00109733 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is EMD Serono, which has 71 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which recombinant human growth hormone is the first listed.
NCT00109733 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00109733 about?
NCT00109733 is a clinical study titled "Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency". The primary objective is to evaluate the efficacy and safety of two different dose regimens of r-hGH (Saizen®) in subjects with childhood-onset growth hormone deficiency (COGHD) during the transition phase from childhood to adulthood.
What is the current status of trial NCT00109733?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 31 participants. The study started on 2005-01. Estimated completion is 2006-07.
What interventions are being tested in trial NCT00109733?
The interventions under investigation include: recombinant human growth hormone (BIOLOGICAL).
Who is sponsoring clinical trial NCT00109733?
This trial is sponsored by EMD Serono, which has 71 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.